Beam Therapeutics IncNASDAQ:BEAM
- LAST PRICE25.1800
- TODAY'S CHANGE (%)-1.4700 (-5.5159%)
- Bid / Lots25.1500/ 1
- Ask / Lots25.2500/ 6
- Open / Previous Close26.4700 / 26.6500
- Day Range
- 52 Week Range
- Volume195,467
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BEAM |
|---|---|---|
| 09:32 ET | 9025 | 27.1 |
| 09:33 ET | 2892 | 26.73 |
| 09:35 ET | 889 | 26.31 |
| 09:37 ET | 1398 | 26.1506 |
| 09:39 ET | 820 | 26.58 |
| 09:44 ET | 4595 | 26.03 |
| 09:46 ET | 1400 | 25.605 |
| 09:48 ET | 10125 | 25.77 |
| 09:50 ET | 3451 | 25.73 |
| 09:51 ET | 5692 | 25.86 |
| 09:53 ET | 2788 | 25.91 |
| 09:55 ET | 1500 | 25.83 |
| 09:57 ET | 7764 | 26 |
| 10:00 ET | 600 | 25.93 |
| 10:02 ET | 3326 | 25.905 |
| 10:04 ET | 1345 | 25.87 |
| 10:06 ET | 2139 | 25.66 |
| 10:08 ET | 1991 | 25.675 |
| 10:09 ET | 2936 | 25.83 |
| 10:11 ET | 1800 | 25.54 |
| 10:13 ET | 800 | 25.58 |
| 10:15 ET | 2708 | 25.6 |
| 10:18 ET | 3116 | 25.41 |
| 10:20 ET | 819 | 25.5196 |
| 10:22 ET | 100 | 25.38 |
| 10:24 ET | 1100 | 25.29 |
| 10:26 ET | 2535 | 25.37 |
| 10:27 ET | 200 | 25.38 |
| 10:29 ET | 1040 | 25.41 |
| 10:31 ET | 1597 | 25.405 |
| 10:33 ET | 519 | 25.395 |
| 10:36 ET | 100 | 25.41 |
| 10:38 ET | 400 | 25.4 |
| 10:40 ET | 2439 | 25.41 |
| 10:42 ET | 400 | 25.335 |
| 10:44 ET | 1564 | 25.42 |
| 10:45 ET | 377 | 25.375 |
| 10:47 ET | 4514 | 25.33 |
| 10:49 ET | 2732 | 25.22 |
| 10:51 ET | 1000 | 25.235 |
| 10:54 ET | 6699 | 25.28 |
| 10:56 ET | 18220 | 25.445 |
| 10:58 ET | 500 | 25.455 |
| 11:00 ET | 1436 | 25.43 |
| 11:02 ET | 1739 | 25.55 |
| 11:03 ET | 2125 | 25.61 |
| 11:05 ET | 2730 | 25.435 |
| 11:07 ET | 200 | 25.44 |
| 11:09 ET | 200 | 25.43 |
| 11:12 ET | 215 | 25.25 |
| 11:14 ET | 686 | 25.1833 |
| 11:16 ET | 578 | 25.135 |
| 11:18 ET | 470 | 25.18 |
Nov 12, 2024
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
DJ Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
DJ Beam Therapeutics Is Maintained at Sector Perform by RBC Capital, from 11:10AM ET on Wednesday Nov 06, 2024 by Dow Jones
11:10AM ET on Wednesday Nov 06, 2024 by Dow JonesDJ Beam Therapeutics Raised to Outperform From Market Perform by Leerink Partners, from 7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting, from 9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beam Therapeutics Inc | 2.1B | -14.6x | --- |
Genmab A/S | 13.8B | 20.4x | +22.71% |
Catalyst Pharmaceuticals Inc | 2.6B | 18.4x | --- |
Galapagos NV | 1.8B | -28.4x | --- |
BioCryst Pharmaceuticals Inc | 1.6B | -12.1x | --- |
Twist Bioscience Corp | 2.5B | -12.9x | --- |
Company Information
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Contact Information
- Headquarters
- 238 Main StreetCAMBRIDGE, MA, United States 02142
- Phone
- 857-327-8775
- Fax
- 302-655-5049
Executives
- President
- Giuseppe Ciaramella
- Chief Executive Officer, Principal Financial and Accounting Officer, Director
- John Evans
- Chief Medical Officer
- Amy Simon
- Chief Legal Officer and Secretary
- Christine Bellon
- Lead Independent Director
- Mark Fishman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
|---|---|
Revenue (TTM) | $349.6M |
Shares Outstanding | 82.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.89 |
EPS | $-1.72 |
Book Value | $12.02 |
P/E Ratio | -14.6x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -52.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
